Introduction of geneType tests to new markets

Genetic Technologies Limited (ASX: $GTG) has announced the expansion of geneType's suite of genetic risk assessment tests to Canada and New Zealand. This expansion marks a four-fold increase in the company's international presence in the second quarter of 2024. The distribution of geneType risk assessment tests in the new territories will be overseen by Stayhealthy Canada and Stayhealthy New Zealand, respectively.

Executive Commentary on Expansion and Sales Growth

We are anticipating accelerated growth as we enter Canada and New Zealand. Coupled with our expansion into new territories, our full-scale marketing efforts have successfully increased consumer awareness and trust that is translating into unprecedented growth. - geneType CEO Simon Morriss

Summary of Expansion and Future Outlook

Genetic Technologies' expansion of geneType tests to Canada and New Zealand reflects the company's strategic efforts to broaden its international presence. The recent success in the digital transformation strategy and pilot influencer campaign has resulted in a remarkable 500% increase in week over week sales. The company's geneType assessment tests cover a wide range of diseases and provide actionable recommendations, demonstrating the company's commitment to proactive healthcare. With ongoing development of clinical-grade assessments for new cancers and chronic conditions, Genetic Technologies is poised for continued growth and innovation in the genomics-based testing market.